You are viewing the site in preview mode

Skip to main content

Advertisement

Table 4 Pre- and post-booster immune response to pneumococcal polysaccharides (ATP persistence and booster ATP immunogenicity cohorts)

From: A randomised trial to evaluate the immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzaeprotein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Singapore and Malaysia

  ClinCom group ComCom group
  Pre-booster dose Post-booster dose Pre-booster dose Post-booster dose
  N % ≥0.2 μg/mL GMC N % ≥0.2 μg/mL GMC N % ≥0.2 μg/mL GMC N % ≥0.2 μg/mL GMC
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
Vaccine serotypes
Serotype 1 111 85.6 0.48 107 100 7.14 112 75.0 0.35 111 100 6.29
(77.6 – 91.5) (0.40 – 0.57)   (96.6 – 100) (6.12 – 8.32)   (65.9 – 82.7) (0.30 – 0.41)   (96.7 – 100) (5.38 – 7.35)
Serotype 4 107 86.9 0.56 106 100 7.53 106 82.1 0.48 109 100 7.43
(79.0 – 92.7) (0.48 – 0.67)   (96.6 – 100) (6.44 – 8.80)   (73.4 – 88.8) (0.40 – 0.58)   (96.7 – 100) (6.33 – 8.71)
Serotype 5 103 92.2 0.76 106 100 7.91 103 91.3 0.54 108 100 7.16
(85.3 – 96.6) (0.65 – 0.89)   (96.6 – 100) (6.91 – 9.06)   (84.1 – 95.9) (0.47 – 0.63)   (96.6 – 100) (6.25 – 8.20)
Serotype 6B 103 71.8 0.34 106 100 3.30 102 60.8 0.32 109 98.2 3.12
(62.1 – 80.3) (0.29 – 0.40)   (96.6 – 100) (2.85 – 3.81)   (50.6 – 70.3) (0.25 – 0.41)   (93.5 – 99.8) (2.59 – 3.76)
Serotype 7F 104 95.2 0.88 106 100 9.02 105 96.2 0.91 109 100 9.25
(89.1 – 98.4) (0.75 – 1.03)   (96.6 – 100) (7.77 – 10.47)   (90.5 – 99.0) (0.78 – 1.07)   (96.7 – 100) (8.04 – 10.64)
Serotype 9V 105 98.1 0.90 107 100 9.36 102 94.1 0.73 109 100 10.42
(93.3 – 99.8) (0.77 – 1.06)   (96.6 – 100) (8.15 – 10.75)   (87.6 – 97.8) (0.62 – 0.85)   (96.7 – 100) (8.94 – 12.14)
Serotype 14 105 93.3 1.06 106 100 13.03 100 93.0 0.91 106 100 13.28
(86.7 – 97.3) (0.86 – 1.31)   (96.6 – 100) (10.95 – 15.50)   (86.1 – 97.1) (0.75 – 1.11)   (96.6 – 100) (11.06 – 15.95)
Serotype 18C 109 92.7 0.83 106 100 19.80 108 92.6 0.78 108 100 24.19
(86.0 – 96.8) (0.69 – 1.01)   (96.6 – 100) (17.02 – 23.03)   (85.9 – 96.7) (0.65 – 0.93)   (96.6 – 100) (20.66 – 28.33)
Serotype 19F 103 98.1 1.10 106 100 19.68 103 99.0 0.96 108 100 20.55
(93.2 – 99.8) (0.87 – 1.40)   (96.6 – 100) (17.22 – 22.51)   (94.7 – 100) (0.82 – 1.13)   (96.6 – 100) (17.62 – 23.98)
Serotype 23F 108 83.3 0.66 107 99.1 7.19 106 79.2 0.47 109 100 6.83
(74.9 – 89.8) (0.51 – 0.84)   (94.9 – 100) (5.94 – 8.71)   (70.3 – 86.5) (0.38 – 0.58)   (96.7 – 100) (5.77 – 8.07)
Cross-reactive serotypes
Serotype 6A 109 53.2 0.23 106 99.1 2.13 111 45.0 0.21 108 97.2 1.99
(43.4 – 62.8) (0.18 – 0.28)   (94.9 – 100) (1.70 – 2.66)   (35.6 – 54.8) (0.16 – 0.26)   (92.1 – 99.4) (1.60 – 2.49)
Serotype 19A 112 49.1 0.18 106 93.4 2.13 109 46.8 0.19 109 96.3 2.96
(39.5 – 58.7) (0.14 – 0.22)   (86.9 – 97.3) (1.65 – 2.76)   (37.2 – 56.6) (0.15 – 0.24)   (90.9 – 99.0) (2.26 – 3.87)
  1. ClinCom = group of toddlers from Singapore primed with the Phase III Clinical lot of PHiD-CV who received the Commercial lot of PHiD-CV in the booster vaccination phase.
  2. ComCom = group of toddlers from Singapore primed with the Commercial lot of PHiD-CV who received the Commercial lot of PHiD-CV in the booster vaccination phase.
  3. N = number of participants with available results.
  4. 95% CI = 95% confidence interval.
  5. % = percentage of infants with antibody concentrations above the specified cut-off.
  6. GMC = geometric mean concentration.